Amylyx Pharmaceuticals, Inc. (AMLX) vs Dyne Therapeutics, Inc. (DYN)
A side-by-side comparison of Amylyx Pharmaceuticals, Inc. and Dyne Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AMLX
Amylyx Pharmaceuticals, Inc.
$27.66HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT
DYN
Dyne Therapeutics, Inc.
$15.15HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT
Total return — AMLX vs DYN
growth of $100 · dividends reinvested · last 5yAMLX +53.7% (+9.0%/yr)DYN +41.9% (+7.3%/yr)AMLX compounded faster over this window
AMLX DYN
AMLX vs DYN: by the numbers
- •AMLX is the larger company ($3.08B vs $2.83B market cap).
Metrics side by side
Valuation
| Metric | AMLX | DYN |
|---|---|---|
| P/B ratio | 12.86 | 4.03 |
Profitability
| Metric | AMLX | DYN |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -63.59% | -73.97% |
| ROIC | -66.60% | -58.28% |
Growth (annualized)
| Metric | AMLX | DYN |
|---|---|---|
| Total return CAGR (5Y) | N/A | -0.38% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.